använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.


Vator Securities advises Empros Pharma on 40 MSEK private placement

4 July 2019

Subscribers in the issue are both existing shareholders Thomas Eldered, Directors of the Board and Management as well as new shareholders with extensive investment experience from the Life Science sector. Thomas Eldered remains the main shareholder in the Company.

Read More

Vator Securities advises Xbrane Biopharma on 238 MSEK Directed and Rights Issue

2 June 2019

The subscribers in the Directed Share Issue are, amongst other, STADA Arzneimittel AG, NYIP (Nyenburgh Investment Partners), Swedbank Robur Medica, Belsize Asset Management GmbH and Serendipity Group AB.

Read More

Xlucane Product Launch Insight with STADA and Xbrane Biopharma

12 April 2019

Vator Securities hosted a Product Launch Insight event for Xlucane together with German STADA Arzneimittel and Xbrane Biopharma yesterday, 11 April 2019.

Read More

Vator Securities advises Xbrane Biopharma on SEK 59 million Rights Issue

29 March 2019

Vator Securities acted Financial Adviser in connection with the transaction raising SEK 59 million.

Read More

Schibsted, Resurs Bank och Moore Strategic Ventures invest in Dicopay

29 March 2019

Dicopay, the leading supplier of digital and mobile services for invoicing and direct payments, announced today that it has raised SEK 42 million to help accelerate the roll out of its services and expand its offering.The investment round was led by Schibsted Growth, and also includes Resurs Bank as an investor and commercial partner, and Moore Strategic Ventures as an investor and financial partner.

Read More

Vator Securities advises Ascelia Pharma on SEK 200 million IPO

6 March 2019

Vator Securities acted as Sole Global Coordinator and Bookrunner in the oversubscribed Ascelia Pharma IPO offer. The new share issue (the “Offering”) will provide Ascelia Pharma with approximately SEK 200 million before deductions for expenses related to the Offering.

Read More

Vator Securities advises Visiopharm on a DKK100 million private placement

24 August 2018

ATP, the Danish Growth Fund and the C. L. David Foundation and Collection are among the new investors. The increased capital commitment is an essential part of the company’s growth strategy within the field of tissue diagnostics- and research software for cancer.

Read More

Vator Securities Sole Bookrunner in Nanoform SEK 71 million private placement

5 July 2018

The private placement was directed to Swedish and Finnish, HNWI, family offices and institutional investors where Mandatum Life Insurance Company (Sampo Group) acted as anchor investor.

Read More